Eiger BioPharmaceuticals, Inc.

EIGR

US28249U2042

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:59:47 2024-04-26 pm EDT			5-day change	1st Jan Change
2.67 ^USD	-12.17%		+11.72%	-60.36%

Apr. 10	Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index	CI
Apr. 08	Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Ldon Mayer Iii Notifies Eiger BioPharmaceuticals, Inc. of His Resignation as the Chief Commercial Officer, Effective February 2, 2024

January 24, 2024 at 05:00 pm EST

On January 18, 2024, Eldon Mayer III notified Eiger BioPharmaceuticals, Inc. of his resignation as the Company?s Chief Commercial Officer, to be effective February 2, 2024.

Latest news about Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index	Apr. 09	CI
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from S&P TMI Index	Apr. 03	CI
Eiger BioPharmaceuticals, Inc. Announces Resignation of Jeffrey S. Glenn as Member of the Board of Directors	Apr. 03	CI
News Highlights : Top Company News of the Day - Tuesday at 1 AM ET	Apr. 02	DJ
News Highlights : Top Company News of the Day - Monday at 11 PM ET	Apr. 01	DJ
News Highlights : Top Company News of the Day - Monday at 9 PM ET	Apr. 01	DJ
Health Care Down as Obesity-Drug Optimism Fades -- Health Care Roundup	Apr. 01	DJ
News Highlights : Top Company News of the Day - Monday at 5 PM ET	Apr. 01	DJ
News Highlights : Top Company News of the Day - Monday at 7 PM ET	Apr. 01	DJ
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01	MT
News Highlights : Top Company News of the Day - Monday at 3 PM ET	Apr. 01	DJ
Top Midday Decliners	Apr. 01	MT
Sector Update: Health Care	Apr. 01	MT
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection; Shares Fall	Apr. 01	MT
Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.	Apr. 01	CI
Motion for Joint Administration Filed by Eiger BioPharmaceuticals, Inc.	Apr. 01	CI
Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy	Apr. 01	CI
Eiger BioPharmaceuticals, Inc. Announces Christine A. Murray Notifies Resignation as Member of Board of Directors, Effective March 15, 2024	Mar. 11	CI
Ldon Mayer Iii Notifies Eiger BioPharmaceuticals, Inc. of His Resignation as the Chief Commercial Officer, Effective February 2, 2024	Jan. 24	CI
Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	Jan. 19	MT
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	Jan. 18	CI
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Moshe Arkin Sends a Letter to Eiger BioPharmaceuticals	Nov. 24	CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs	Nov. 16	DJ

Chart Eiger BioPharmaceuticals, Inc.

Duration

Period

More charts

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Eiger BioPharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.67 USD

Average target price

30 USD

Spread / Average Target

+1,023.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EIGER BIOPHARMACEUTICALS, INC.	-60.36%	3.95M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

Eiger BioPharmaceuticals, Inc.

Equities

EIGR

US28249U2042

Biotechnology & Medical Research

Ldon Mayer Iii Notifies Eiger BioPharmaceuticals, Inc. of His Resignation as the Chief Commercial Officer, Effective February 2, 2024

Latest news about Eiger BioPharmaceuticals, Inc.

Chart Eiger BioPharmaceuticals, Inc.

Company Profile

Income Statement Evolution

Ratings for Eiger BioPharmaceuticals, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research